1
|
Erikson JM, Valente AJ, Mummidi S, Kandikattu HK, DeMarco VG, Bender SB, Fay WP, Siebenlist U, Chandrasekar B. Targeting TRAF3IP2 by Genetic and Interventional Approaches Inhibits Ischemia/Reperfusion-induced Myocardial Injury and Adverse Remodeling. J Biol Chem 2017; 292:2345-2358. [PMID: 28053087 DOI: 10.1074/jbc.m116.764522] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Revised: 12/07/2016] [Indexed: 11/06/2022] Open
Abstract
Re-establishing blood supply is the primary goal for reducing myocardial injury in subjects with ischemic heart disease. Paradoxically, reperfusion results in nitroxidative stress and a marked inflammatory response in the heart. TRAF3IP2 (TRAF3 Interacting Protein 2; previously known as CIKS or Act1) is an oxidative stress-responsive cytoplasmic adapter molecule that is an upstream regulator of both IκB kinase (IKK) and c-Jun N-terminal kinase (JNK), and an important mediator of autoimmune and inflammatory responses. Here we investigated the role of TRAF3IP2 in ischemia/reperfusion (I/R)-induced nitroxidative stress, inflammation, myocardial dysfunction, injury, and adverse remodeling. Our data show that I/R up-regulates TRAF3IP2 expression in the heart, and its gene deletion, in a conditional cardiomyocyte-specific manner, significantly attenuates I/R-induced nitroxidative stress, IKK/NF-κB and JNK/AP-1 activation, inflammatory cytokine, chemokine, and adhesion molecule expression, immune cell infiltration, myocardial injury, and contractile dysfunction. Furthermore, Traf3ip2 gene deletion blunts adverse remodeling 12 weeks post-I/R, as evidenced by reduced hypertrophy, fibrosis, and contractile dysfunction. Supporting the genetic approach, an interventional approach using ultrasound-targeted microbubble destruction-mediated delivery of phosphorothioated TRAF3IP2 antisense oligonucleotides into the LV in a clinically relevant time frame significantly inhibits TRAF3IP2 expression and myocardial injury in wild type mice post-I/R. Furthermore, ameliorating myocardial damage by targeting TRAF3IP2 appears to be more effective to inhibiting its downstream signaling intermediates NF-κB and JNK. Therefore, TRAF3IP2 could be a potential therapeutic target in ischemic heart disease.
Collapse
Affiliation(s)
- John M Erikson
- From the Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229
| | - Anthony J Valente
- From the Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229
| | - Srinivas Mummidi
- From the Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229
| | - Hemanth Kumar Kandikattu
- the Department of Medicine, University of Missouri School of Medicine, Columbia, Missouri 65211.,the Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65201
| | - Vincent G DeMarco
- the Department of Medicine, University of Missouri School of Medicine, Columbia, Missouri 65211.,the Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65201.,the Departments of Medical Pharmacology and Physiology and
| | - Shawn B Bender
- the Departments of Medical Pharmacology and Physiology and.,the Dalton Cardiovascular Research Center, Columbia, Missouri 65201, and.,Biomedical Sciences, University of Missouri School of Medicine, Columbia, Missouri 65211
| | - William P Fay
- the Department of Medicine, University of Missouri School of Medicine, Columbia, Missouri 65211.,the Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65201.,the Departments of Medical Pharmacology and Physiology and
| | - Ulrich Siebenlist
- Biomedical Sciences, University of Missouri School of Medicine, Columbia, Missouri 65211.,the Laboratory of Immunoregulation, NIAID, National Institutes of Health, Bethesda, Maryland 20892
| | - Bysani Chandrasekar
- the Department of Medicine, University of Missouri School of Medicine, Columbia, Missouri 65211, .,the Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65201.,the Departments of Medical Pharmacology and Physiology and.,the Dalton Cardiovascular Research Center, Columbia, Missouri 65201, and
| |
Collapse
|
2
|
Garcia RA, Go KV, Villarreal FJ. Effects of timed administration of doxycycline or methylprednisolone on post-myocardial infarction inflammation and left ventricular remodeling in the rat heart. Mol Cell Biochem 2006; 300:159-69. [PMID: 17149544 DOI: 10.1007/s11010-006-9379-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2006] [Accepted: 11/06/2006] [Indexed: 10/23/2022]
Abstract
The development of strategies to ameliorate post-myocardial infarction (MI) remodeling and improve function continues to be an area of clinical importance. Use of steroids for this purpose is controversial since the effects of timed treatment on relevant inflammatory, biochemical and structure/function endpoints are unclear. In a previous report, we demonstrated that use of doxycycline pre-treatment improves post-MI remodeling and passive left ventricular (LV) function. However, the effects of timed doxycycline post-MI treatment are unknown. To examine these issues, we performed a study using a rat MI model. Animals were administered one of the following: doxycycline (DOX), the corticosteroid methylprednisolone (MP), or aqueous vehicle. Treatment was given early, short-term (at time of MI to 24 h post-MI) or late, long term (2-7 days post-MI). Animals were sacrificed at 3, 7 or 42 days post-surgery. We assessed LV hemodynamics, pressure-volume, and pressure-scar strains, histomorphometry, inflammation via measurements of myeloperoxidase activity, and matrix metalloproteinase (MMP) activity. Late MP treatment yielded a robust right-shifted pressure-volume curve, which was accompanied by increased scar strains. Late DOX treatment yielded reduced average heart weight and size and preserved scar thickness. DOX treatment did not suppress inflammation, which contrasts with the suppressive effects of MP. Use of early or late MP yielded increased MMP activity in infarcted and non-infarcted regions. Early and late treatment with DOX yielded infarct-associated MMP activity levels comparable to those of vehicle-treated animals. In conclusion, results indicate that late use of MP yields adverse post-MI structure/function outcomes that correlate with suppression of inflammation and increased MMP activity. These observations contrast with those of DOX, in particular, late treatment where improved outcomes were observed in LV structure and were accompanied by the lack of suppression of inflammation.
Collapse
Affiliation(s)
- Ricardo A Garcia
- Department of Medicine, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | | | | |
Collapse
|